GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Gross Margin %

LSB (LakeShore Biopharma Co) Gross Margin % : 81.92% (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. LakeShore Biopharma Co's Gross Profit for the three months ended in Sep. 2023 was $10.87 Mil. LakeShore Biopharma Co's Revenue for the three months ended in Sep. 2023 was $13.27 Mil. Therefore, LakeShore Biopharma Co's Gross Margin % for the quarter that ended in Sep. 2023 was 81.92%.


The historical rank and industry rank for LakeShore Biopharma Co's Gross Margin % or its related term are showing as below:

LSB' s Gross Margin % Range Over the Past 10 Years
Min: 76.72   Med: 77.24   Max: 80.89
Current: 80.89


During the past 4 years, the highest Gross Margin % of LakeShore Biopharma Co was 80.89%. The lowest was 76.72%. And the median was 77.24%.

LSB's Gross Margin % is ranked better than
76.27% of 746 companies
in the Biotechnology industry
Industry Median: 60.565 vs LSB: 80.89

LakeShore Biopharma Co had a gross margin of 81.92% for the quarter that ended in Sep. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for LakeShore Biopharma Co was 0.00% per year.


LakeShore Biopharma Co Gross Margin % Historical Data

The historical data trend for LakeShore Biopharma Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Gross Margin % Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Gross Margin %
76.79 76.72 77.68 79.48

LakeShore Biopharma Co Quarterly Data
Mar21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only 78.07 - 80.33 81.92 -

Competitive Comparison of LakeShore Biopharma Co's Gross Margin %

For the Biotechnology subindustry, LakeShore Biopharma Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Gross Margin % falls into.



LakeShore Biopharma Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

LakeShore Biopharma Co's Gross Margin for the fiscal year that ended in Mar. 2024 is calculated as

Gross Margin % (A: Mar. 2024 )=Gross Profit (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=63.3 / 79.625
=(Revenue - Cost of Goods Sold) / Revenue
=(79.625 - 16.342) / 79.625
=79.48 %

LakeShore Biopharma Co's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=10.9 / 13.267
=(Revenue - Cost of Goods Sold) / Revenue
=(13.267 - 2.399) / 13.267
=81.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


LakeShore Biopharma Co  (NAS:LSB) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

LakeShore Biopharma Co had a gross margin of 81.92% for the quarter that ended in Sep. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


LakeShore Biopharma Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.